Tolmetin β-D-Glucuronide NEW
Price | $592 |
Package | 1mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Tolmetin β-D-Glucuronide | CAS No.: 71595-19-2 |
Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Tolmetin β-D-Glucuronide |
Description | Tolmetin β-D-Glucuronide has reactive properties with human serum albumin, allowing identification of the binding site and reaction mechanism by tandem mass spectrometry. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : Slightly soluble Methanol : Slightly soluble, Heating is recommended. |
Keywords | Tolmetin beta-D-Glucuronide | Tolmetin β-D-Glucuronide | Tolmetin b-D-Glucuronide | Tolmetin β D Glucuronide | Tolmetin βDGlucuronide |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$0.00/1G |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2023-02-20 | |
$77.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-11 | |
$1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-06-15 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY